“…12,13,18,19 When bound within the coding region of a gene, polyamides do not represent an obstacle for elongating RNA polymerase, which can readily disrupt the polyamide/double-stranded DNA complex. 20 However, linkage of DNA-modifying agents to the polyamide, such as chlorambucil (Chl) 21 or CC-1065/CBI derivatives, 22 which covalently react with the DNA at the polyamide binding-site, can inhibit transcription by stalling RNA polymerase during elongation. 23 One concern for the use of polyamide-alkylator conjugates in cancer therapeutics is whether these molecules will discriminate between tumor and normal cells, which is the main problem with conventional DNA alkylators that are currently used in cancer therapy.…”